Antibody-mediated rejection in cardiac transplantation: Emerging knowledge in diagnosis and management: A scientific statement from the American Heart Association: Endorsed by the international society for heart and lung transplantation

Circulation

Volumn 131, Issue 18, 2015, Pages 1608-1639

  Colvin, Monica M ^a   Cook, Jennifer L ^a   Chang, Patricia ^a   Francis, Gary ^a   Hsu, Daphne T ^a   Kiernan, Michael S ^a   Kobashigawa, Jon A ^a   Lindenfeld, JoAnn ^a   Masri, Sofia Carolina ^a   Miller, Dylan ^a   O'Connell, John ^a   Rodriguez, E Rene ^a   Rosengard, Bruce ^a   Self, Sally ^a   White Williams, Connie ^a   Zeevi, Adriana ^a  

^a NONE

Author keywords

Allograft; Antibody mediated rejection; Cardiac transplantation; Heart transplantation

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; COMPLEMENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ECULIZUMAB; HLA ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LYMPHOCYTE ANTIBODY; MYCOPHENOLATE MOFETIL; RITUXIMAB; ALLOANTIBODY; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN;

ANTIBODY MEDIATED REJECTION; ASSISTED CIRCULATION; CARDIOVASCULAR RISK; DONOR; GRAFT RECIPIENT; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE IRRADIATION; MAINTENANCE THERAPY; MEDICAL SOCIETY; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PUVA; REVIEW; SPLENECTOMY; ADULT; CHILD; CONSENSUS DEVELOPMENT; DISEASE MANAGEMENT; EXTRACORPOREAL OXYGENATION; GRAFT REJECTION; HEART MUSCLE; IMMUNOLOGY; INCIDENCE; MACROPHAGE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PRACTICE GUIDELINE; PROCEDURES; RADIOTHERAPY; RISK FACTOR; UNITED STATES;

ADULT; AMERICAN HEART ASSOCIATION; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CHILD; COMBINED MODALITY THERAPY; COMPLEMENT SYSTEM PROTEINS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DISEASE MANAGEMENT; EXTRACORPOREAL MEMBRANE OXYGENATION; GRAFT REJECTION; HEART TRANSPLANTATION; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; ISOANTIBODIES; LYMPHATIC IRRADIATION; MACROPHAGES; MYOCARDIUM; PHOTOPHERESIS; PLASMAPHERESIS; RISK FACTORS; SPLENECTOMY; UNITED STATES;

EID: 84929377961     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0000000000000093     Document Type: Review

References (282)

1. Reed EF, Demetris AJ, Hammond E, Itescu S, Kobashigawa JA, Reinsmoen NL, Rodriguez ER, Rose M, Stewart S, Suciu-Foca N, Zeevi A, Fishbein MC; International Society for Heart and Lung Transplantation. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant. 2006;25:153-159.
2. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, Reichenspurner H, Angelini A, Berry G, Burke M, Czer L, Hiemann N, Kfoury AG, Mancini D, Mohacsi P, Patel J, Pereira N, Platt JL, Reed EF, Reinsmoen N, Rodriguez ER, Rose ML, Russell SD, Starling R, Suciu-Foca N, Tallaj J, Taylor DO, Van Bakel A, West L, Zeevi A, Zuckermann A; Consensus Conference Participants. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2011;30:252-269.
3. Berry GJ, Angelini A, Burke MM, Bruneval P, Fishbein MC, Hammond E, Miller D, Neil D, Revelo MP, Rodriguez ER, Stewart S, Tan CD, Winters GL, Kobashigawa J, Mehra MR. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J Heart Lung Transplant. 2011;30:601-611.
4. Berry GJ, Burke MM, Andersen C, Bruneval P, Fedrigo M, Fishbein MC, Goddard M, Hammond EH, Leone O, Marboe C, Miller D, Neil D, Rassl D, Revelo MP, Rice A, Rene Rodriguez E, Stewart S, Tan CD, Winters GL, West L, Mehra MR, Angelini A. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2013;32:1147-1162.
5. Billingham ME, Cary NR, Hammond ME, Kemnitz J, Marboe C, McCallister HA, Snovar DC, Winters GL, Zerbe A. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group: the International Society for Heart Transplantation. J Heart Transplant. 1990;9:587-593.
6. Stewart S, Winters G, Fishbein M, Tazelaar H, Kobashigawa J, Abrams J, Andersen C, Angelini A, Berry G, Burke MM, Demetris AJ, Hammond E, Itescu S, Marboe CC, McManus B, Reed EF, Reinsmoen NL, Rodriguez ER, Rose AG, Rose M, Suciu-Focia N, Zeevi A, Billingham ME. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24:1710-1720.
7. Brasile L, Zerbe T, Rabin B, Clarke J, Abrams A, Cerilli J. Identification of the antibody to vascular endothelial cells in patients undergoing cardiac transplantation. Transplantation. 1985;40:672-675.
8. Michaels P, Espejo M, Kobashigawa J, Alejos J, Burch C, Takemoto S, Reed E, Fishbein M. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant. 2003;22:58-69.
9. Taylor DO, Yowell RL, Kfoury AG, Hammond EH, Renlund DG. Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant. 2000;19:518-521.
10. Kfoury A, Hammond M, Snow G, Stehlik J, Reid B, Long J, Gilbert E, Bader F, Bull D. Early screening for antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant. 2007;26:1264-1269.
11. Crespo-Leiro MG, Veiga-Barreiro A, Doménech N, Paniagua MJ, Piñon P, González-Cuesta M, Vázquez-Martul E, Ramirez C, Cuenca JJ, Castro-Beiras A. Humoral heart rejection (severe allograft dysfunction with no signs of cellular rejection or ischemia): incidence, management, and the value of C4d for diagnosis. Am J Transplant. 2005;5:2560-2564.
12. Hammond EH, Yowell RL, Nunoda S, Menlove RL, Renlund DG, Bristow MR, Gay WA Jr, Jones KW, O'Connell JB. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant. 1989;8:430-443.
13. Hathout E, Beeson WL, Kuhn M, Johnston J, Fitts J, Razzouk A, Bailey L, Chinnock RE. Cardiac allograft vasculopathy in pediatric heart transplant recipients. Transpl Int. 2006;19:184-189.
14. Loupy A, Cazes A, Guillemain R, Amrein C, Hedjoudje A, Tible M, Pezzella V, Fabiani JN, Suberbielle C, Nochy D, Hill GS, Empana JP, Jouven X, Bruneval P, Duong Van Huyen JP. Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy. Am J Transplant. 2011;11:1478-1487.
15. Kfoury A, Hammond M, Snow G, Drakos S, Stehlik J, Fisher P, Reid B, Everitt M, Bader FM, Renlund DG. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. J Heart Lung Transplant. 2009;28:781-784.
16. Abrams J, Amir O, Etheridge WB, Frazier OH. Histologic findings proving the existence of humoral rejection in a cardiac allograft. Cardiovasc Pathol. 2007;16:38-42.
17. Ratliff NB, McMahon JT. Activation of intravascular macrophages within myocardial small vessels is a feature of acute vascular rejection in human heart transplants. J Heart Lung Transplant. 1995;14:338-345.
18. Duong Van Huyen JP, Fornes P, Guillemain R, Amrein C, Chevalier P, Latremouille C, Creput C, Glotz D, Nochy D, Bruneval P. Acute vascular humoral rejection in a sensitized cardiac graft recipient: diagnostic value of C4d immunofluorescence. Hum Pathol. 2004;35:385-388.
19. Lones MA, Czer LS, Trento A, Harasty D, Miller JM, Fishbein MC. Clinical-pathologic features of humoral rejection in cardiac allografts: a study in 81 consecutive patients. J Heart Lung Transplant. 1995;14(pt 1):151-162.
20. Loy TS, Bulatao IS, Darkow GV, Demmy TL, Reddy HK, Curtis J, Bickel JT. Immunostaining of cardiac biopsy specimens in the diagnosis of acute vascular (humoral) rejection: a control study. J Heart Lung Transplant. 1993;12:736-740.
21. Trento A, Hardesty RL, Griffith BP, Zerbe T, Kormos RL, Bahnson HT. Role of the antibody to vascular endothelial cells in hyperacute rejection in patients undergoing cardiac transplantation. J Thorac Cardiovasc Surg. 1988;95:37-41.
22. Foerster A. Vascular rejection in cardiac transplantation: a morphological study of 25 human cardiac allografts. APMIS. 1992;100:367-376.
23. Baldwin WM 3rd, Samaniego-Picota M, Kasper EK, Clark AM, Czader M, Rohde C, Zachary AA, Sanfilippo F, Hruban RH. Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes. Transplantation. 1999;68:894-900.
24. Behr TM, Richter K, Fischer P, Spes CH, Meiser B, Reichart B, Pongratz D, Feucht H, Theisen K, Angermann CE. Incidence of humoral rejection in heart transplant recipients treated with tacrolimus or cyclosporine A. Transplant Proc. 1998;30:1920-1921.
25. Behr TM, Feucht HE, Richter K, Reiter C, Spes CH, Pongratz D, Uberfuhr P, Meiser B, Theisen K, Angermann CE. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. J Heart Lung Transplant. 1999;18:904-912.
26. Arias LF, Fernández R, Fernández D, Jaramillo JC, Gil M, López García-Asenjo JA. C4D immunostaining in surveillance endomyocardial biopsies from well-functioning heart allografts. Transplant Proc. 2010;42:1793-1796.
27. Chantranuwat C, Qiao JH, Kobashigawa J, Hong L, Shintaku P, Fishbein MC. Immunoperoxidase staining for C4d on paraffin-embedded tissue in cardiac allograft endomyocardial biopsies: comparison to frozen tissue immunofluorescence. Appl Immunohistochem Mol Morphol. 2004;12:166-171.
28. Fedrigo M, Gambino A, Tona F, Torregrossa G, Poli F, Benazzi E, Frigo A, Feltrin G, Toscano G, Caforio AP, Iliceto S, Valente M, Thiene G, Gerosa G, Angelini A. Can C4d immunostaining on endomyocardial biopsies be considered a prognostic biomarker in heart transplant recipients? [published correction appears in Transplantation. 2011;91:135] Transplantation. 2010;90:791-798.
29. Fedson SE, Daniel SS, Husain AN. Immunohistochemistry staining of C4d to diagnose antibody-mediated rejection in cardiac transplantation. J Heart Lung Transplant. 2008;27:372-379.
30. Moseley EL, Atkinson C, Sharples LD, Wallwork J, Goddard MJ. Deposition of C4d and C3d in cardiac transplants: a factor in the development of coronary artery vasculopathy. J Heart Lung Transplant. 2010;29:417-423.
31. Poelzl G, Ullrich R, Huber A, Ulmer H, Antretter H, Hoefer D, Mairinger T, Laufer G, Pachinger O, Schwarzacher S. Capillary deposition of the complement fragment C4d in cardiac allograft biopsies is associated with allograft vasculopathy. Transpl Int. 2005;18:313-317.
32. Garrett HE Jr, Duvall-Seaman D, Helsley B, Groshart K. Treatment of vascular rejection with rituximab in cardiac transplantation. J Heart Lung Transplant. 2005;24:1337-1342.
33. Almuti K, Haythe J, Dwyer E, Itescu S, Burke E, Green P, Marboe C, Mancini D. The changing pattern of humoral rejection in cardiac transplant recipients. Transplantation. 2007;84:498-503.
34. Nath DS, Angaswamy N, Basha HI, Phelan D, Moazami N, Ewald GA, Mohanakumar T. Donor-specific antibodies to human leukocyte antigens are associated with and precede antibodies to major histocompatibility complex class I-related chain A in antibody-mediated rejection and cardiac allograft vasculopathy after human cardiac transplantation. Hum Immunol. 2010;71:1191-1196.
35. Gonzalez-Stawinski GV, Cook DJ, Chui J, Gupta S, Navia JL, Hoercher K, Taylor DO, Yamani MH, Starling RC, Smedira NG. A comparative analysis between survivors and nonsurvivors with antibody mediated cardiac allograft rejection. J Surg Res. 2007;142:233-238.
36. Bayliss J, Bailey M, Leet A, Stein AN, Thomson NM, McLean CA. Late onset antibody-mediated rejection and endothelial localization of vascular endothelial growth factor are associated with development of cardiac allograft vasculopathy. Transplantation. 2008;86:991-997.
37. Casarez T, Perens G, Williams R, Kutay E, Fishbein M, Reed E, Alejos J, Levi D. Humoral rejection in pediatric orthotopic heart transplantation. J Heart Lung Transplant. 2007;26:114-119.
38. Rodriguez E, Skojec D, Tan C, Zachary A, Kasper E, Conte J, Baldwin W 3rd. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant. 2005;5:2778-2785.
39. Holt DB, Liapis H, Mohanakumar T, Phelan DR, Gandi SK, Huddleston CB, Canter CE. Complement fragment C4d and C3d deposition in pediatric heart recipients with a positive crossmatch. J Heart Lung Transplant. 2008;27:1073-1078.
40. Cadeiras M, Burke E, Dedrick R, Gangadin A, Latif F, Shahzad K, Sinha A, Tabak EG, Marboe CC, Califano AC, Deng MC. Gene expression profiles of patients with antibody-mediated rejection after cardiac transplantation [published correction appears in J Heart Lung Transplant. 2008;27:1190]. J Heart Lung Transplant. 2008;27:932-934.
41. Tan CD, Baldwin WM 3rd, Rodriguez ER. Update on cardiac transplantation pathology. Arch Pathol Lab Med. 2007;131:1169-1191.
42. Baldwin WM 3rd, Qian Z, Ota H, Samaniego M, Wasowska B, Sanfilippo F, Hruban RH. Complement as a mediator of vascular inflammation and activation in allografts. J Heart Lung Transplant. 2000;19:723-730.
43. Aranda JM Jr, Scornik JC, Normann SJ, Lottenberg R, Schofield RS, Pauly DF, Miles M, Hill JA, Sleasman JW, Skoda-Smith S. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation. 2002;73:907-910.
44. Hammond ME, Stehlik J, Snow G, Renlund DG, Seaman J, Dabbas B, Gilbert EM, Stringham JC, Long JW, Kfoury AG; Utah Transplant Affiliated Hospitals (UTAH) Cardiac Transplant Program. Utility of histologic parameters in screening for antibody-mediated rejection of the cardiac allograft: a study of 3,170 biopsies. J Heart Lung Transplant. 2005;24:2015-2021.
45. Kfoury A, Stehlik J, Renlund D, Seaman J, Gilbert E, Stringham J, Long J, Hammond M. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns. J Heart Lung Transplant. 2006;25:1277-1282.
46. Revelo MP, Stehlik J, Miller D, Snow GL, Everitt MD, Budge D, Bader FM, Alharethi RA, Gilbert EM, Reid BB, Selzman CH, Hammond ME, Kfoury AG. Antibody testing for cardiac antibody-mediated rejection: which panel correlates best with cardiovascular death? J Heart Lung Transplant. 2011;30:144-150.
47. Tan CD, Sokos GG, Pidwell DJ, Smedira NG, Gonzalez-Stawinski GV, Taylor DO, Starling RC, Rodriguez ER. Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection. Am J Transplant. 2009;9:2075-2084.
48. Okada M, Yoshioka K, Takemura T, Akano N, Aya N, Murakami K, Maki S. Immunohistochemical localization of C3d fragment of complement and S-protein (vitronectin) in normal and diseased human kidneys: association with the C5b-9 complex and vitronectin receptor. Virchows Arch A Pathol Anat Histopathol. 1993;422:367-373.
49. González-Stawinski GV, Tan CD, Smedira NG, Starling RC, Rodríguez ER. Decay-accelerating factor expression may provide immunoprotection against antibody-mediated cardiac allograft rejection. J Heart Lung Transplant. 2008;27:357-361.
50. Hammond EH, Hansen JK, Spencer LS, Jensen A, Riddell D, Craven CM, Yowell RL. Vascular rejection in cardiac transplantation: histologic, immunopathologic, and ultrastructural features. Cardiovasc Pathol. 1993;2:21-34.
51. Labarrere CA, Pitts D, Halbrook H, Faulk WP. Tissue plasminogen activator, plasminogen activator inhibitor-1, and fibrin as indexes of clinical course in cardiac allograft recipients: an immunocytochemical study. Circulation. 1994;89:1599-1608.
52. Bonnaud EN, Lewis NP, Masek MA, Billingham ME. Reliability and usefulness of immunofluorescence in heart transplantation. J Heart Lung Transplant. 1995;14(pt 1):163-171.
53. Jordan SC, Quartel AW, Czer LS, Admon D, Chen G, Fishbein MC, Schwieger J, Steiner RW, Davis C, Tyan DB. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation. 1998;66:800-805.
54. Fishbein MC, Kobashigawa J. Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy. Curr Opin Cardiol. 2004;19:166-169.
55. Tambur AR, Leventhal J, Kaufman DB, Friedewald J, Miller J, Abecassis MM. Tailoring antibody testing and how to use it in the calculated panel reactive antibody era: the Northwestern University experience. Transplantation. 2008;86:1052-1059.
56. Smith JD, Danskine AJ, Rose ML, Yacoub MH. Specificity of lymphocytotoxic antibodies formed after cardiac transplantation and correlation with rejection episodes. Transplantation. 1992;53:1358-1362.
57. Fenoglio J, Ho E, Reed E, Rose E, Smith C, Reemstma K, Marboe C, Suciu-Foca N. Anti-HLA antibodies and heart allograft survival. Transplant Proc. 1989;21:807-809.
58. Reed EF, Hong B, Ho E, Harris PE, Weinberger J, Suciu-Foca N. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease. Transplantation. 1996;61:566-572.
59. Kaczmarek I, Deutsch M, Kauke T, Beiras-Fernandez A, Schmoeckel M, Vicol C, Sodian R, Reichart B, Spannagl M, Ueberfuhr P. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. Exp Clin Transplant. 2008;6:229-235.
60. George JF, Kirklin JK, Shroyer TW, Naftel DC, Bourge RC, McGiffin DC, White-Williams C, Noreuil T. Utility of posttransplantation panel-reactive antibody measurements for the prediction of rejection frequency and survival of heart transplant recipients. J Heart Lung Transplant. 1995;14:856-864.
61. Leech S, Mather P, Eisen H, Pina I, Margulies K, Bove A, Jeevanandam V. Donor-specific HLA antibodies after transplantation are associated with deterioration in cardiac function. Clin Transplant. 1996;10:639-645.
62. Carter V, Shenton BK, Jaques B, Turner D, Talbot D, Gupta A, Chapman CE, Matthews CJ, Cavanagh G. Vimentin antibodies: a non-HLA antibody as a potential risk factor in renal transplantation. Transplant Proc. 2005;37:654-657.
63. Sumitran-Holgersson S, Wilczek H, Holgersson J, Soderstrom K. Identification of the nonclassical HLA molecules, MICA, as targets for humoral immunity associated with irreversible rejection of kidney allografts1. Transplantation. 2002;74:268-277.
64. Suárez-Alvarez B, López-Vázquez A, Gonzalez MZ, Fdez-Morera JL, Díaz-Molina B, Blanco-Gelaz MA, Pascual D, Martínez-Borra J, Muro M, Alvarez-López MR, López-Larrea C. The relationship of anti-MICA antibodies and MICA expression with heart allograft rejection. Am J Transplant. 2007;7:1842-1848.
65. Rose ML. Role of MHC and non-MHC alloantibodies in graft rejection. Curr Opin Organ Transplant. 2004;9:16-22.
66. Ferry BL, Welsh KI, Dunn MJ, Law D, Proctor J, Chapel H, Yacoub MH, Rose ML. Anti-cell surface endothelial antibodies in sera from cardiac and kidney transplant recipients: association with chronic rejection. Transpl Immunol. 1997;5:17-24.
67. Fredrich R, Toyoda M, Czer L, Galfayan K, Galera O, Trento A, Freimark D, Young S, Jordan SC. The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Transplantation. 1999;67:385-391.
68. Faulk WP, Rose M, Meroni PL, Del Papa N, Torry RJ, Labarrere CA, Busing K, Crisp SJ, Dunn MJ, Nelson DR. Antibodies to endothelial cells identify myocardial damage and predict development of coronary artery disease in patients with transplanted hearts. Hum Immunol. 1999;60:826-832.
69. Jurcevic S, Ainsworth ME, Pomerance A, Smith JD, Robinson DR, Dunn MJ, Yacoub MH, Rose ML. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation. 2001;71:886-892.
70. Alvarez-Márquez A, Aguilera I, Blanco RM, Pascual D, Encarnación-Carrizosa M, Alvarez-López MR, Wichmann I, Nuñez-Roldán A. Positive association of anticytoskeletal endothelial cell antibodies and cardiac allograft rejection. Hum Immunol. 2008;69:143-148.
71. Azimzadeh AM, Pfeiffer S, Wu GS, Schröder C, Zhou H, Zorn GL 3rd, Kehry M, Miller GG, Rose ML, Pierson RN 3rd. Humoral immunity to vimentin is associated with cardiac allograft injury in nonhuman primates. Am J Transplant. 2005;5:2349-2359.
72. Nath DS, Ilias Basha H, Tiriveedhi V, Alur C, Phelan D, Ewald GA, Moazami N, Mohanakumar T. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy. J Heart Lung Transplant. 2010;29:1277-1285.
73. Ensley RD, Hammond EH, Renlund DG, Yowell RL, Bristow MR, DeWitt CW, Menlove RL, Ratkovec RM, O'Connell JB. Clinical manifestations of vascular rejection in cardiac transplantation. Transplant Proc. 1991;23(pt 2):1130-1132.
74. Cherry R, Nielsen H, Reed E, Reemtsma K, Suciu-Foca N, Marboe CC. Vascular (humoral) rejection in human cardiac allograft biopsies: relation to circulating anti-HLA antibodies. J Heart Lung Transplant. 1992;11:24-29.
75. Miller L, Wesp A, Jennison S, Graham M, Martin T, McBride L, Pennington D, Peigh P. Vascular rejection in heart transplant recipients. J Heart Lung Transplant. 1993;12:S147-S152.
76. Caple JF, McMahon JT, Myles JL, Hook S, Ratliff NB. Acute vascular (humoral) rejection in non-OKT3-treated cardiac transplants. Cardiovasc Pathol. 1995;4:13-18.
77. Smith R, Brousaides N, Grazette L, Saidman S, Semigran M, Disalvo T, Madsen J, Dec G, Perez-Atayde A, Collins A. C4d deposition in cardiac allografts correlates with alloantibody. J Heart Lung Transplant. 2005;24:1202-1210.
78. Holt DB, Lublin DM, Phelan DL, Boslaugh SE, Gandhi SK, Huddleston CB, Saffitz JE, Canter CE. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy. J Heart Lung Transplant. 2007;26:876-882.
79. Hammond EH, Wittwer CT, Greenwood J, Knape WA, Yowell RL, Menlove RL, Craven C, Renlund DG, Bristow MR, DeWitt CW, O'Connell JB. Relationship of OKT3 sensitization and vascular rejection in cardiac transplant patients receiving OKT3 rejection prophylaxis. Transplantation. 1990;50:776-782.
80. Olsen S, Wagoner L, Hammond E, Taylor D, Yowell R, Ensley R, Bristow M, O'Connell J, Renlund D. Vascular rejection in heart transplantation: clinical correlation, treatment options, and future considerations. J Heart Lung Transplant. 1993;12:S135-S142.
81. Loupy A, Suberbielle-Boissel C, Hill G, Lefaucheur C, Anglicheau D, Zuber J, Martinez F, Thervet E, Méjean A, Charron D, Duong van Huyen JP, Bruneval P, Legendre C, Nochy D. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donorspecific antibodies. Am J Transplant. 2009;9:2561-2570.
82. Kraus E, Parekh R, Oberai P, Lepley D, Segev D, Bagnasco S, Collins V, Leffell M, Lucas D, Rabb H, Racusen LC, Singer AL, Stewart ZA, Warren DS, Zachary AA, Haas M, Montgomery RA. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant. 2009;9:1826-1834.
83. Koch CA, Khalpey ZI, Platt JL. Accommodation: preventing injury in transplantation and disease. J Immunol. 2004;172:5143-5148.
84. Grauhan O, Knosalla C, Ewert R, Hummel M, Loebe M, Weng YG, Hetzer R. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. J Heart Lung Transplant. 2001;20:316-321.
85. Wu G, Kobashigawa J, Fishbein M, Patel J, Kittleson M, Reed E, Kiyosaki K, Ardehali A. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant. 2009;28:417-422.
86. Kfoury AG, Renlund DG, Snow GL, Stehlik J, Folsom JW, Fisher PW, Reid BB, Clayson SE, Gilbert EM, Everitt MD, Bader FM, Singhal AK, Hammond ME. A clinical correlation study of severity of antibody-mediated rejection and cardiovascular mortality in heart transplantation. J Heart Lung Transplant. 2009;28:51-57.
87. Yoshida S, Takeuchi K, Del Nido P, Ho C. Diastolic dysfunction coincides with early mild transplant rejection: in situ measurements in a heterotopic rat heart transplant model. J Heart Lung Transplant. 1998;17:1049-1056.
88. Sachdeva R, Malik S, Seib PM, Frazier EA, Cleves MA. Doppler tissue imaging and catheter-derived measures are not independent predictors of rejection in pediatric heart transplant recipients. Int J Cardiovasc Imaging. 2011;27:947-954.
89. Palka P, Lange A, Galbraith A, Duhig E, Clarke BE, Parsonage W, Donnelly JE, Stafford WJ, Burstow DJ. The role of left and right ventricular early diastolic Doppler tissue echocardiographic indices in the evaluation of acute rejection in orthotopic heart transplant. J Am Soc Echocardiogr. 2005;18:107-115.
90. Branch KR, Caldwell JH, Soine L, O'Brien KD. Vascular (humoral) cardiac allograft rejection manifesting as inducible myocardial ischemia on nuclear perfusion imaging. J Nucl Cardiol. 2005;12:123-124.
91. Almenar L, Igual B, Martínez-Dolz L, Arnau M, Osa A, Rueda J, Palencia M. Utility of cardiac magnetic resonance imaging for the diagnosis of heart transplant rejection. Transplant Proc. 2003;35:1962-1964.
92. Marie PY, Angioi¯ M, Carteaux JP, Escanye JM, Mattei S, Tzvetanov K, Claudon O, Hassan N, Danchin N, Karcher G, Bertrand A, Walker PM, Villemot JP. Detection and prediction of acute heart transplant rejection with the myocardial T2 determination provided by a black-blood magnetic resonance imaging sequence. J Am Coll Cardiol. 2001;37:825-831.
93. Smart FW, Ballantyne CM, Cocanougher B, Farmer JA, Sekela ME, Noon GP, Young JB. Insensitivity of noninvasive tests to detect coronary artery vasculopathy after heart transplant. Am J Cardiol. 1991;67:243-247.
94. Mousseaux E, Farge D, Guillemain R, Amrein C, Vulser C, Bruneval P, Gaux JC, Carpentier A. Magnetic resonance imaging of human transplanted hearts with gadolinium-DOTA myocardial enhancement: potential use for the detection of rejection. J Am Coll Cardiol. 1991;17(2s1):A326. Abstract.
95. Rivard AL, Swingen CM, Blake D, Huang AS, Kanth P, Thomsen GF, Cordova EJ, Miller LW, Bianco RW, Wilke N. A comparison of myocardial perfusion and rejection in cardiac transplant patients. Int J Cardiovasc Imaging. 2007;23:575-582.
96. Lund G, Morin R, Olivari M, Ring W. Serial myocardial T2 relaxation time measurements in normal subjects and heart transplant recipients. J Heart Transplant. 1988;7:274-279.
97. Wisenberg G, Pflugfelder PW, Kostuk WJ, McKenzie FN, Prato FS. Diagnostic applicability of magnetic resonance imaging in assessing human cardiac allograft rejection. Am J Cardiol. 1987;60:130-136.
98. Butler CR, Thompson R, Haykowsky M, Toma M, Paterson I. Cardiovascular magnetic resonance in the diagnosis of acute heart transplant rejection: a review. J Cardiovasc Magn Reson. 2009;11:7.
99. Abdel-Aty H, Boyé P, Zagrosek A, Wassmuth R, Kumar A, Messroghli D, Bock P, Dietz R, Friedrich MG, Schulz-Menger J. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol. 2005;45:1815-1822.
100. De Cobelli F, Pieroni M, Esposito A, Chimenti C, Belloni E, Mellone R, Canu T, Perseghin G, Gaudio C, Maseri A, Frustaci A, Del Maschio A. Delayed gadolinium-enhanced cardiac magnetic resonance in patients with chronic myocarditis presenting with heart failure or recurrent arrhythmias. J Am Coll Cardiol. 2006;47:1649-1654.
101. Aletras AH, Tilak GS, Natanzon A, Hsu LY, Gonzalez FM, Hoyt RF, Arai AE. Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. Circulation. 2006;113:1865-1870.
102. Sasaguri S, LaRaia PJ, Fabri BM, Fallon JT, Ayelsworth CA, D'Ambra MN, Newell JB, Brady TJ, Buckley MJ. Early detection of cardiac allograft rejection with proton nuclear magnetic resonance. Circulation. 1985;72(pt 2):II231-II236.
103. Estep JD, Shah DJ, Nagueh SF, Mahmarian JJ, Torre-Amione G, Zoghbi WA. The role of multimodality cardiac imaging in the transplanted heart. JACC Cardiovasc Imaging. 2009;2:1126-1140.
104. Miller DV, Roden AC, Gamez JD, Tazelaar HD. Detection of C4d deposition in cardiac allografts: a comparative study of immunofluorescence and immunoperoxidase methods. Arch Pathol Lab Med. 2010;134:1679-1684.
105. Johnson M, Aaronson KD, Canter C, Kirklin J, Mancini D, Mehra M, Radovancevic B, Taylor D, Webber S. Heart retransplantation. Am J Transplant. 2007;7:2075-2081.
106. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, Fedson S, Fisher P, Gonzales-Stawinski G, Martinelli L, McGiffin D, Smith J, Taylor D, Meiser B, Webber S, Baran D, Carboni M, Dengler T, Feldman D, Frigerio M, Kfoury A, Kim D, Kobashigawa J, Shullo M, Stehlik J, Teuteberg J, Uber P, Zuckermann A, Hunt S, Burch M, Bhat G, Canter C, Chinnock R, Crespo-Leiro M, Delgado R, Dobbels F, Grady K, Kao W, Lamour J, Parry G, Patel J, Pini D, Towbin J, Wolfel G, Delgado D, Eisen H, Goldberg L, Hosenpud J, Johnson M, Keogh A, Lewis C, O'Connell J, Rogers J, Ross H, Russell S, Vanhaecke J. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914-956.
107. Sivasankaran S, Pollard-Quintner S, Sachdeva R, Pugeda J, Hoq SM, Zarich SW. The effect of a six-week program of yoga and meditation on brachial artery reactivity: do psychosocial interventions affect vascular tone? Clin Cardiol. 2006;29:393-398.
108. Vieira CA, Agarwal A, Book BK, Sidner RA, Bearden CM, Gebel HM, Roggero AL, Fineberg NS, Taber T, Kraus MA, Pescovitz MD. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1: safety, pharmacodynamics, and pharmacokinetics. Transplantation. 2004;77:542-548.
109. Clatworthy MR, Friend PJ, Calne RY, Rebello PR, Hale G, Waldmann H, Watson CJ. Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. Transplantation. 2009;87:1092-1095.
110. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Tevar A, Woodle ES. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008;86:1754-1761.
111. Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, Hill G, Glotz D, Suberbielle-Boissel C. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant. 2009;9:1099-1107.
112. Stegall M, Gloor J, Winters J, Moore S, Degoey S. A Comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant. 2006;6:346-351.
113. Twombley K, Thach L, Ribeiro A, Joseph C, Seikaly M. Acute antibody-mediated rejection in pediatric kidney transplants: a single center experience. Pediatr Transplant. 2013;17:E149-E155.
114. Venetz JP, Pascual M. New treatments for acute humoral rejection of kidney allografts. Expert Opin Investig Drugs. 2007;16:625-633.
115. Goodwin W, Kaufman J, Mims M, Turner R, Glassock R, Goldman R, Maxwell M. Human renal transplantation, I: clinical experiences with six cases of renal homotransplantation. J Urol. 1963;89:13-24.
116. Taylor D, Meiser B, Webber S, Baran DA, Carboni M, Dengler T, Feldman D, Frigerio M, Kfoury A, Kim D, Kobashigawa J, Shullo M, Stehlik J, Teuteberg J, Uber PA, West L, Zuckermann A. Task Force 2: Immunosuppression and Rejection. In: The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:926-933.
117. Lindenfeld J, Miller G, Shakar S, Zolty R, Lowes B, Wolfel E, Mestroni L, Page R, Kobashigawa J. Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs. Circulation. 2004;110:3734-3740.
118. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270:286-290.
119. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270:283-286.
120. Gelfand EW. Antibody-directed therapy: past, present, and future. J Allergy Clin Immunol. 2001;108(suppl):S111-S116.
121. Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology. 2002;59(suppl 6):S13-S21.
122. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med. 1992;326:107-116.
123. Singh N, Pirsch J, Samaniego M. Antibody-mediated rejection: treatment alternatives and outcomes. Transplant Rev (Orlando). 2009;23:34-46.
124. Velez M, Johnson MR. Management of allosensitized cardiac transplant candidates. Transplant Rev (Orlando). 2009;23:235-247.
125. Wang SS, Chou NK, Ko WJ, Chi NH, Hung SC, Hsu RB, Yu HY, Chen YS, Chu SH, Tsao CI, Shun CT. Effect of plasmapheresis for acute humoral rejection after heart transplantation. Transplant Proc. 2006;38:3692-3694.
126. Leech SH, Rubin S, Eisen HJ, Mather PJ, Goldman BI, McClurken JB, Furukawa S. Cardiac transplantation across a positive prospective lymphocyte cross-match in sensitized recipients. Clin Transplant. 2003;17(suppl 9):17-26.
127. Leech SH, Lopez-Cepero M, LeFor WM, DiChiara L, Weston M, Furukawa S, Macha M, Singhal A, Wald JW, Nikolaidis LA, McClurken JB, Bove AA. Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin. Clin Transplant. 2006;20:476-484.
128. Ratkovec RM, Hammond EH, O'Connell JB, Bristow MR, DeWitt CW, Richenbacher WE, Millar RC, Renlund DG. Outcome of cardiac transplant recipients with a positive donor-specific crossmatch-preliminary results with plasmapheresis. Transplantation. 1992;54:651-655.
129. John R, Lietz K, Burke E, Ankersmit J, Mancini D, Suciu-Foca N, Edwards N, Rose E, Oz M, Itescu S. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation. 1999;100(suppl):II229-II235.
130. Marques M, Schwartz J. Update on extracorporeal photopheresis in heart and lung transplantation. J Clin Apher. 2011;26:146-151.
131. Marques MB, Tuncer HH. Photopheresis in solid organ transplant rejection. J Clin Apher. 2006;21:72-77.
132. Lamioni A, Parisi F, Isacchi G, Giorda E, Di Cesare S, Landolfo A, Cenci F, Bottazzo GF, Carsetti R. The immunological effects of extracorporeal photopheresis unraveled: induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation. 2005;79:846-850.
133. Meloni F, Cascina A, Miserere S, Perotti C, Vitulo P, Fietta AM. Peripheral CD4(+)CD25(+) TREG cell counts and the response to extracorporeal photopheresis in lung transplant recipients. Transplant Proc. 2007;39:213-217.
134. George JF, Gooden CW, Guo L, Kirklin JK. Role for CD4(+)CD25(+) T cells in inhibition of graft rejection by extracorporeal photopheresis [published correction appears in J Heart Lung Transplant. 2008;27:1190]. J Heart Lung Transplant. 2008;27:616-622.
135. Costanzo-Nordin MR, Hubbell EA, O'Sullivan EJ, Johnson MR, Mullen GM, Heroux AL, Kao WG, McManus BM, Pifarre R, Robinson JA. Photopheresis versus corticosteroids in the therapy of heart transplant rejection: preliminary clinical report. Circulation. 1992;86:II242-II250.
136. Dall'Amico R, Livi U, Milano A, Montini G, Andreetta B, Murer L, Zacchello G, Thiene G, Casarotto D, Zacchello F. Extracorporeal photochemotherapy as adjuvant treatment of heart transplant recipients with recurrent rejection. Transplantation. 1995;60:45-49.
137. Dall'Amico R, Montini G, Murer L, Andreetta B, Zacchello G, Gambino A, Feltrin G, Caforio A, Tursi V, Livi U. Extracorporeal photochemotherapy after cardiac transplantation: a new therapeutic approach to allograft rejection. Int J Artif Organs. 2000;23:49-54.
138. Wieland M, Thiede VL, Strauss RG, Piette WW, Kapelanski DP, Landas SK, Hunsicker LG, Vance SJ, Randels MJ. Treatment of severe cardiac allograft rejection with extracorporeal photochemotherapy. J Clin Apher. 1994;9:171-175.
139. Costanzo-Nordin MR, Hubbell EA, O'Sullivan EJ, Johnson MR, Mullen GM, Heroux AL, Kao WG, McManus BM, Pifarre R, Robinson JA. Successful treatment of heart transplant rejection with photopheresis. Transplantation. 1992;53:808-815.
140. Kirklin JK, Brown RN, Huang ST, Naftel DC, Hubbard SM, Rayburn BK, McGiffin DC, Bourge RB, Benza RL, Tallaj JA, Pinderski LJ, Pamboukian SV, George JF, Marques M. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. J Heart Lung Transplant. 2006;25:283-288.
141. Barr ML, Meiser BM, Eisen HJ, Roberts RF, Livi U, Dall'Amico R, Dorent R, Rogers JG, Radovančević B, Taylor DO, Jeevanandam V, Marboe CC. Photopheresis for the prevention of rejection in cardiac transplantation. N Engl J Med. 1998;339:1744-1751.
142. Barr M, Baker C, Schenkel F, McLaughlin S, Stouch B, Starnes V, Rose E. Prophylactic photopheresis and chronic rejection: effects on graft intimal hyperplasia in cardiac transplantation. Clin Transplant. 2000;14:162-166.
143. Ballester M, Obrador D, Carrió I, Bordes R, Augé JM, Crexells C, Oriol A, Padró JM, Aris A, Caralps JM. Reversal of rejection-induced coronary vasculitis detected early after heart transplantation with increased immunosuppression. J Heart Transplant. 1989;8:413-417.
144. Malafa M, Mancini MC, Myles JL, Gohara A, Dickinson JM, Walsh TE. Successful treatment of acute humoral rejection in a heart transplant patient. J Heart Lung Transplant. 1992;11:486-491.
145. Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, Costanzo M, Eisen H, Dureau G, Ratkovec R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F, Valantine H. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients: Mycophenolate Mofetil Investigators. Transplantation. 1998;66:507-515.
146. Costanzo-Nordin MR, O'Sullivan EJ, Johnson MR, Winters GL, Pifarre R, Radvany R, Zucker MJ, Scanlon PJ, Robinson JA. Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation. J Heart Transplant. 1990;9:306-315.
147. Griffith B, Kormos R, Armitage J, Dummer J, Hardesty R. Comparative trial of immunoprophylaxis with RATG versus OKT3. J Heart Transplant. 1990;9:301-305.
148. Deeb GM, Bolling SF, Steimle CN, Dawe JE, McKay AL, Richardson AM. A randomized prospective comparison of MALG with OKT3 for rescue therapy of acute myocardial rejection. Transplantation. 1991;51:180-183.
149. Kirklin JK, Bourge RC, White-Williams C, Naftel DC, Thomas FT, Thomas JM, Phillips MG. Prophylactic therapy for rejection after cardiac transplantation: a comparison of rabbit antithymocyte globulin and OKT3. J Thorac Cardiovasc Surg. 1990;99:716-724.
150. Weigensberg M, Morecki S, Weiss L, Fuks Z, Slavin S. Suppression of cell-mediated immune responses after total lymphoid irradiation (TLI), I: characterization of suppressor cells of the mixed lymphocyte reaction. J Immunol. 1984;132:971-978.
151. Baldwin WM 3rd, Armstrong LP, Samaniego-Picota M, Rahimi S, Zachary AA, Kasper EK, Conte JV, Hruban RH, Rodriguez ER. Antithymocyte globulin is associated with complement deposition in cardiac transplant biopsies. Hum Immunol. 2004;65:1273-1280.
152. Colovai AI, Vasilescu ER, Foca-Rodi A, Kim-Schulze S, Hussaini N, D'Agati VD, Markowitz GS, Wang C, Cohen DJ, Hardy MA, Suciu-Foca N. Acute and hyperacute humoral rejection in kidney allograft recipients treated with anti-human thymocyte antibodies. Hum Immunol. 2005;66:501-512.
153. Maldonado AQ, Davies NM, Crow SA, Little C, Ojogho ON, Weeks DL. Effects of plasmapheresis on mycophenolic acid concentrations. Transplantation. 2011;91:e3-e4.
154. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant. 2004;4:996-1001.
155. Bittner HB, Dunitz J, Hertz M, Bolman MR 3rd, Park SJ. Hyperacute rejection in single lung transplantation: case report of successful management by means of plasmapheresis and antithymocyte globulin treatment. Transplantation. 2001;71:649-651.
156. Hammond EA, Yowell RL, Greenwood J, Hartung L, Renlund D, Wittwer C. Prevention of adverse clinical outcome by monitoring of cardiac transplant patients for murine monoclonal CD3 antibody (OKT3) sensitization. Transplantation. 1993;55:1061-1063.
157. Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med. 1999;134:445-450.
158. Baran DA, Lubitz S, Alvi S, Fallon JT, Kaplan S, Galin I, Correa R, Courtney MC, Chan M, Spielvogel D, Lansman SL, Gass AL. Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab. Transplant Proc. 2004;36:3164-3166.
159. Garrett HE Jr, Groshart K, Duvall-Seaman D, Combs D, Suggs R. Treatment of humoral rejection with rituximab. Ann Thorac Surg. 2002;74:1240-1242.
160. Kaczmarek I, Deutsch MA, Sadoni S, Brenner P, Schmauss D, Daebritz SH, Weiss M, Meiser BM, Reichart B. Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review. J Heart Lung Transplant. 2007;26:511-515.
161. Keren A, Hayes HM, O'Driscoll G. Late humoral rejection in a cardiac transplant recipient treated with the anti-CD20 monoclonal antibody rituximab. Transplant Proc. 2006;38:1520-1522.
162. Balfour IC, Fiore A, Graff RJ, Knutsen AP. Use of rituximab to decrease panel-reactive antibodies. J Heart Lung Transplant. 2005;24:628-630.
163. McGee EC Jr, Cotts W, Tambur AR, Friedewald J, Kim J, O'Connell J, Wallace S, McCarthy PM. Successful bridge to transplant in a highly sensitized patient with a complicated pump pocket infection. J Heart Lung Transplant. 2008;27:568-571.
164. Frampton JE, Wagstaff AJ. Alemtuzumab. Drugs. 2003;63:1229-1243.
165. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood. 1993;82:807-812.
166. Morris PJ, Russell NK. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation. 2006;81:1361-1367.
167. Ciancio G, Burke GW, Gaynor JJ, Sageshima J, Herrada E, Tueros L, Roth D, Kupin W, Rosen A, Esquenazi V, Miller J. Campath-1H induction therapy in African American and Hispanic first renal transplant recipients: 3-year actuarial follow-up. Transplantation. 2008;85:507-516.
168. Ciancio G, Burke GW 3rd. Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant. 2008;8:15-20.
169. Ciancio G, Gaynor JJ, Roth D, Kupin W, Hanson L, Tueros L, Zarak A, Ruiz P, Burke GW 3rd. Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. Transplant Proc. 2010;42:3503-3506.
170. McCurry KR, Iacono A, Zeevi A, Yousem S, Girnita A, Husain S, Zaldonis D, Johnson B, Hattler BG, Starzl TE. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg. 2005;130:528-537.
171. Shyu S, Dew MA, Pilewski JM, Devito Dabbs AJ, Zaldonis DB, Studer SM, Crespo MM, Toyoda Y, Bermudez CA, McCurry KR. Five-year outcomes with alemtuzumab induction after lung transplantation. J Heart Lung Transplant. 2011;30:743-754.
172. van Loenhout KC, Groves SC, Galazka M, Sherman B, Britt E, Garcia J, Griffith B, Iacono A. Early outcomes using alemtuzumab induction in lung transplantation. Interact Cardiovasc Thorac Surg. 2010;10:190-194.
173. Thomas PG, Woodside KJ, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation. 2007;83:1509-1512.
174. Ciancio G, Gaynor JJ, Guerra G, Sageshima J, Chen L, Mattiazzi A, Roth D, Kupin W, Tueros L, Flores S, Hanson L, Vianna R, Burke GW 3rd. Randomized trial of three induction antibodies in kidney transplantation: long-term results. Transplantation. 2014;97:1128-1138.
175. Ciancio G, Sageshima J, Akpinar E, Gaynor JJ, Chen L, Zarak A, Hanson L, Tueros L, Guerra G, Mattiazzi A, Kupin W, Roth D, Ricordi C, Burke GW 3rd. A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab. Transplantation. 2013;96:800-806.
176. Ciancio G, Gaynor JJ, Sageshima J, Guerra G, Zarak A, Roth D, Brown R, Kupin W, Chen L, Hanson L, Tueros L, Ruiz P, Livingstone AS, Burke GW 3rd. Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation. Transplantation. 2011;92:1348-1357.
177. Reams B, Musselwhite L, Zaas D, Steele M, Garantziotis S, Eu P, Snyder L, Curl J, Lin S, Davis R, Palmer SM. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am J Transplant. 2007;7:2802-2808.
178. Basu A, Ramkumar M, Tan H, Khan A, McCauley J, Marcos A, Fung J, Starzl T, Shapiro R. Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc. 2005;37:923-926.
179. Das B, Shoemaker L, Recto M, Austin E, Dowling R. Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use. J Heart Lung Transplant. 2008;27:242-244.
180. Wang H, Arp J, Liu W, Faas SJ, Jiang J, Gies DR, Ramcharran S, Garcia B, Zhong R, Rother RP. Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. J Immunol. 2007;179:4451-4463.
181. Woodside KJ, Lick SD. Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection. J Heart Lung Transplant. 2007;26:750-752.
182. Eckman PM, Hanna M, Taylor DO, Starling RC, Gonzalez-Stawinski GV. Management of the sensitized adult heart transplant candidate. Clin Transplant. 2010;24:726-734.
183. Kyle RA, Rajkumar SV. Multiple myeloma [published correction appears in N Engl J Med. 2005;352:1163]. N Engl J Med. 2004;351:1860-1873.
184. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
185. Everly JJ, Walsh RC, Alloway RR, Woodle ES. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant. 2009;14:662-666.
186. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, Candon S, Martinez F, Snanoudj R, Rabant M, Pallet N, Nochy D, Anglicheau D, Leruez M, Loupy A, Thervet E, Hermine O, Legendre C. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant. 2010;10:681-686.
187. Trivedi HL, Terasaki PI, Feroz A, Everly MJ, Vanikar AV, Shankar V, Trivedi VB, Kaneku H, Idica AK, Modi PR, Khemchandani SI, Dave SD. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation. 2009;87:1555-1561.
188. Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, Stegall MD. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant. 2009;9:201-209.
189. Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, Drachenberg CB, Gibson IW, Grimm PC, Haas M, Lerut E, Liapis H, Mannon RB, Marcus PB, Mengel M, Mihatsch MJ, Nankivell BJ, Nickeleit V, Papadimitriou JC, Platt JL, Randhawa P, Roberts I, Salinas-Madriga L, Salomon DR, Seron D, Sheaff M, Weening JJ. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant. 2007;7:518-526.
190. Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233-1243.
191. Hill A, Hillmen P, Richards SJ, Elebute D, Marsh JC, Chan J, Mojcik CF, Rother RP. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:2559-2565.
192. Rother RP, Arp J, Jiang J, Ge W, Faas SJ, Liu W, Gies DR, Jevnikar AM, Garcia B, Wang H. C5 blockade with conventional immunosuppression induces long-term graft survival in presensitized recipients. Am J Transplant. 2008;8:1129-1142.
193. Pruitt SK, Bollinger RR. The effect of soluble complement receptor type 1 on hyperacute allograft rejection. J Surg Res. 1991;50:350-355.
194. Wang H, Jiang J, Liu W, Kubelik D, Chen G, Gies D, Garcia B, Zhong R, Rother RP. Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine. Transplantation. 2005;79:1121-1127.
195. Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011;11:2405-2413.
196. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85-118.
197. Lietz K, John R, Schuster M, Ankersmit J, Burke E, Suciu-Foca N, Edwards N, Mancini D, Itescu S. Mycophenolate mofetil reduces anti-HLA antibody production and cellular rejection in heart transplant recipients. Transplant Proc. 2002;34:1828-1829.
198. Rose AG. Understanding the pathogenesis and the pathology of hyperacute cardiac rejection. Cardiovasc Pathol. 2002;11:171-176.
199. Weigel G, Griesmacher A, Karimi A, Zuckermann AO, Grimm M, Mueller MM. Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients. J Heart Lung Transplant. 2002;21:1074-1079.
200. Hamburger J, Vaysse J, Crosnier J, Auvert J, Lalanne CM, Hopper J Jr. Renal homotransplantation in man after radiation of the recipient: experience with six patients since 1959. Am J Med. 1962;32:854-871.
201. Slavin S, Reitz B, Bieber CP, Kaplan HS, Strober S. Transplantation tolerance in adult rats using total lymphoid irradiation: permanent survival of skin, heart, and marrow allografts. J Exp Med. 1978;147:700-707.
202. Kahn DR, Hong R, Greenberg AJ, Gilbert EF, Dacumos GC, Dufek JH. Total lymphatic irradiation and bone marrow in human heart transplantation. Ann Thorac Surg. 1984;38:169-171.
203. Winterland AW, Frist WH, Eisert DR, Stroup S. Total lymphoid irradiation to treat recurrent heart rejection. Clin Transpl. 1989:323.
204. Frist WH, Winterland AW, Gerhardt EB, Merrill WH, Atkinson JB, Eastburn TE, Stewart JR, Eisert DR. Total lymphoid irradiation in heart transplantation: adjunctive treatment for recurrent rejection. Ann Thorac Surg. 1989;48:863-864.
205. Hunt SA, Strober S, Hoppe RT, Stinson EB. Total lymphoid irradiation for treatment of intractable cardiac allograft rejection. J Heart Lung Transplant. 1991;10:211-216.
206. Salter SP, Salter MM, Kirklin JK, Bourge RC, Naftel DC. Total lymphoid irradiation in the treatment of early or recurrent heart transplant rejection. Int J Radiat Oncol Biol Phys. 1995;33:83-88.
207. Wolden SL, Tate DJ, Hunt SA, Strober S, Hoppe RT. Long-term results of total lymphoid irradiation in the treatment of cardiac allograft rejection. Int J Radiat Oncol Biol Phys. 1997;39:953-960.
208. Madden BP, Barros J, Backhouse L, Stamenkovic S, Tait D, Murday A. Intermediate term results of total lymphoid irradiation for the treatment of non-specific graft dysfunction after heart transplantation. Eur J Cardiothorac Surg. 1999;15:663-666.
209. Madden BP, Backhouse L, McClosky D, Reynolds L, Tait D, Murday A. Total lymphoid irradiation as rescue therapy after heart transplantation. J Heart Lung Transplant. 1996;15:234-238.
210. Evans MA, Schomberg PJ, Rodeheffer RJ, Katzmann JA, Schnell WA Jr, Tazelaar HD, McGregor CG, Edwards BS. Total lymphoid irradiation: a novel and successful therapy for resistant cardiac allograft rejection. Mayo Clinic Proc. 1992;67:785-790.
211. Ross HJ, Gullestad L, Pak J, Slauson S, Valantine HA, Hunt SA. Methotrexate or total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: a comparative study. J Heart Lung Transplant. 1997;16:179-189.
212. Valentine VG, Robbins RC, Wehner JH, Patel HR, Berry GJ, Theodore J. Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts. Chest. 1996;109:1184-1189.
213. Lim TS, O'Driscoll G, Freund J, Peterson V, Hayes H, Heywood J. Short-course total lymphoid irradiation for refractory cardiac transplantation rejection. J Heart Lung Transplant. 2007;26:1249-1254.
214. Trachiotis GD, Johnston TS, Vega JD, Crocker IR, Chesnut N, Lutz JF, Smith AL, Kanter KR. Single-field total lymphoid irradiation in the treatment of refractory rejection after heart transplantation. J Heart Lung Transplant. 1998;17:1045-1048.
215. Ghadjar P, Joos D, Martinelli M, Hullin R, Zwahlen M, Lossl K, Carrel T, Aebersold DM, Mohacsi P. Tailored total lymphoid irradiation in heart transplant patients: 10-years experience of one center. Radiat Oncol. 2010;5:3.
216. Pelletier MP, Coady M, Macha M, Oyer PE, Robbins RC. Coronary atherosclerosis in cardiac transplant patients treated with total lymphoid irradiation. J Heart Lung Transplant. 2003;22:124-129.
217. Salter MM, Kirklin JK, Bourge RC, Naftel DC, White-Williams C, Tarkka M, Waits E, Bucy RP. Total lymphoid irradiation in the treatment of early or recurrent heart rejection. J Heart Lung Transplant. 1992;11:902-911.
218. Locke J, Zachary A, Haas M, Melancon J, Warren D, Simpkins C, Segev D, Montgomery R. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant. 2007;7:842-846.
219. Takahashi K, Saito K, Takahara S, Okuyama A, Tanabe K, Toma H, Uchida K, Hasegawa A, Yoshimura N, Kamiryo Y; Japanese ABO-Incompatible Kidney Transplantation Committee. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant. 2004;4:1089-1096.
220. Uchida J, Machida Y, Iwai T, Naganuma T, Kitamoto K, Iguchi T, Maeda S, Kamada Y, Kuwabara N, Kim T, Nakatani T. Desensitization protocol in highly HLA-sensitized and ABO-incompatible high titer kidney transplantation. Transplant Proc. 2010;42:3998-4002.
221. Ishida H, Omoto K, Shimizu T, Shirakawa H, Nishida H, Xiaobei L, Yamaguchi Y, Tanabe K. Usefulness of splenectomy for chronic active antibody-mediated rejection after renal transplantation. Transpl Int. 2008;21:602-604.
222. Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation. 2002;74:1207-1210.
223. Gloor JM, Lager DJ, Fidler ME, Grande JP, Moore SB, Winters JL, Kremers WK, Stegall MD. A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation. 2005;80:1572-1577.
224. Kaplan B, Gangemi A, Thielke J, Oberholzer J, Sankary H, Benedetti E. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation. 2007;83:99-100.
225. Alexander J. The late adverse effect of splenectomy on patient survival following cadaveric renal transplantation. Transplantation. 1984;37:467-470.
226. Marasco SF, Esmore DS, Negri J, Rowland M, Newcomb A, Rosenfeldt FL, Bailey M, Richardson M. Early institution of mechanical support improves outcomes in primary cardiac allograft failure. J Heart Lung Transplant. 2005;24:2037-2042.
227. Arpesella G, Loforte A, Mikus E, Mikus PM. Extracorporeal membrane oxygenation for primary allograft failure. Transplant Proc. 2008;40:3596-3597.
228. Leprince P, Aubert S, Bonnet N, Rama A, Léger P, Bors V, Levasseur J, Szefner J, Vaissier E, Pavie A. Peripheral extracorporeal membrane oxygenation (ECMO) in patients with posttransplant cardiac graft failure. Transplant Proc. 2005;37:2879-2880.
229. Santise G, Petrou M, Pepper JR, Dreyfus G, Khaghani A, Birks EJ. Levitronix as a short-term salvage treatment for primary graft failure after heart transplantation. J Heart Lung Transplant. 2006;25:495-498.
230. Tenderich G, Koerner MM, Stuettgen B, Minami K, El-Banayosy A, Arusoglu L, Mirow N, Wlost S, Gromzik H, Kleesiek K, Meyer H, Koerfer R. Mechanical circulatory support after orthotopic heart transplantation. Int J Artif Organs. 1998;21:414-416.
231. Listijono DR, Watson A, Pye R, Keogh AM, Kotlyar E, Spratt P, Granger E, Dhital K, Jansz P, Macdonald PS, Hayward CS. Usefulness of extracorporeal membrane oxygenation for early cardiac allograft dysfunction. J Heart Lung Transplant. 2011;30:783-789.
232. Chou N-K, Chi N-H, Ko W-J, Yu H-Y, Huang S-C, Wang S-S, Lin F-Y, Chu S-H, Chen Y-S. Extracorporeal membrane oxygenation for perioperative cardiac allograft failure. ASAIO J. 2006;52:100-103. 10.1097/01.mat.0000196514.69525.d9.
233. Kavarana MN, Sinha P, Naka Y, Oz MC, Edwards NM. Mechanical support for the failing cardiac allograft: a single-center experience. J Heart Lung Transplant. 2003;22:542-547.
234. Mihaljevic T, Jarrett CM, Gonzalez-Stawinski G, Smedira NG, Nowicki ER, Thuita L, Mountis M, Blackstone EH. Mechanical circulatory support after heart transplantation. Eur J Cardiothorac Surg. 2012;41:200-206.
235. D'Alessandro C, Aubert S, Golmard JL, Praschker BL, Luyt CE, Pavie A, Gandjbakhch I, Leprince P. Extra-corporeal membrane oxygenation temporary support for early graft failure after cardiac transplantation. Eur J Cardiothorac Surg. 2010;37:343-349.
236. Stendahl G, Berger S, Ellis T, Gandy K, Mitchell M, Tweddell J, Zangwill S. Humoral rejection after pediatric heart transplantation: a case report. Prog Transplant. 2010;20:288-291.
237. Saito S, Matsumiya G, Fukushima N, Sakaguchi T, Fujita T, Ueno T, Miyagawa S, Yamauchi A, Sawa Y. Successful treatment of cardiogenic shock caused by humoral cardiac allograft rejection. Circ J. 2009;73:970-973.
238. Morales DLS, Braud BE, Price JF, Dreyer WJ, Denfield SW, Clunie SK, Heinle JS, Fraser CD Jr. Use of mechanical circulatory support in pediatric patients with acute cardiac graft rejection. ASAIO J. 2007;53:701-705.
239. Kittleson MM, Patel JK, Moriguchi JD, Kawano M, Davis S, Hage A, Hamilton MA, Esmailian F, Kobashigawa JA. Heart transplant recipients supported with extracorporeal membrane oxygenation: outcomes from a single-center experience. J Heart Lung Transplant. 2011;30:1250-1256.
240. Heidt S, Roelen DL, Eijsink C, van Kooten C, Claas FHJ, Mulder A. Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin [published correction appears in Transplantation. 2009;87:307]. Transplantation. 2008;86:1292-1300.
241. Schmid C, Garritsen HS, Kelsch R, Cassens U, Baba HA, Sibrowski W, Scheld HH. Suppression of panel-reactive antibodies by treatment with mycophenolate mofetil. Thorac Cardiovasc Surg. 1998;46:161-162.
242. Ishida H, Furusawa M, Murakami T, Tokumoto T, Nakajima I, Tanabe K, Fuchinoue S, Toma H. Outcome of an AB0-incompatible renal transplant without splenectomy. Transpl Int. 2002;15:56-58.
243. Mannami M, Mitsuhata N. Improved outcomes after ABO-incompatible living-donor kidney transplantation after 4 weeks of treatment with mycophenolate mofetil. Transplantation. 2005;79:1756-1758.
244. Taylor DO, Bristow MR, O'Connell JB, Ensley RD, Olsen SL, Hammond EH, Wagoner LE, Renlund DG. A prospective, randomized comparison of cyclophosphamide and azathioprine for early rejection prophylaxis after cardiac transplantation: decreased sensitization to OKT3. Transplantation. 1994;58:645-649.
245. Zhu LP, Cupps TR, Whalen G, Fauci A. Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest. 1987;79:1082-1090.
246. Hammond EH, Yowell RL, Price GD, Menlove RL, Olsen SL, O'Connell JB, Bristow MR, Doty DB, Millar RC, Karwande SV. Vascular rejection and its relationship to allograft coronary artery disease. J Heart Lung Transplant. 1992;11(pt 2):S111-S119.
247. Crespo-Leiro MG. Calcineurin inhibitors in heart transplantation. Transplant Proc. 2005;37:4018-4020.
248. Bacal F, Sodré GL, Fernandes DA, Aiello VD, Stolf N, Bocchi E, Bellotti G. Methotrexate in acute persistent humoral rejection: an option for graft rescue. Ann Thorac Surg. 2003;76:607-610.
249. Costanzo-Nordin M, Grusk B, Silver M, Sobotka P, Winters G, O'Connell J, Pifarré R, Robinson J. Reversal of recalcitrant cardiac allograft rejection with methotrexate. Circulation. 1988;78(pt 2):III47-III57.
250. Nair N, Ball T, Uber PA, Mehra MR. Current and future challenges in therapy for antibody-mediated rejection. J Heart Lung Transplant. 2011;30:612-617.
251. Chih S, Tinckam KJ, Ross HJ. A survey of current practice for antibody-mediated rejection in heart transplantation. Am J Transplant. 2013;13:1069-1074.
252. Pahl E. Transplant coronary artery disease in children. Prog Pediatr Cardiol. 2000;11:137-143.
253. Zales VR, Crawford S, Backer CL, Lynch P, Benson DW Jr, Mavroudis C. Spectrum of humoral rejection after pediatric heart transplantation. J Heart Lung Transplant. 1993;12:563-571.
254. Everitt MD, Pahl E, Schechtman KB, Zheng J, Ringewald JM, Ecuyer TL, Naftel DC, Kirklin JK, Blume ED, Bullock EA, Canter CE. Rejection with hemodynamic compromise in the current era of pediatric heart transplantation: a multi-institutional study. J Heart Lung Transplant. 2011;30:282-288.
255. Pahl E, Naftel DC, Canter CE, Frazier EA, Kirklin JK, Morrow WR; Pediatric Heart Transplant Study. Death after rejection with severe hemodynamic compromise in pediatric heart transplant recipients: a multiinstitutional study. J Heart Lung Transplant. 2001;20:279-287.
256. Phelps CM, Tissot C, Buckvold S, Gralla J, Dunbar Ivy D, Pietra BA, Miyamoto SD. Outcome of acute graft rejection associated with hemodynamic compromise in pediatric heart transplant recipients. Pediatr Cardiol. 2011;32:1-7.
257. Webber SA, Naftel DC, Parker J, Mulla N, Balfour I, Kirklin JK, Morrow R; Pediatric Heart Transplant Study Group. Late rejection episodes more than 1 year after pediatric heart transplantation: risk factors and outcomes. J Heart Lung Transplant. 2003;22:869-875.
258. Wright EJ, Fiser WP, Edens RE, Frazier EA, Morrow WR, Imamura M, Jaquiss RD. Cardiac transplant outcomes in pediatric patients with preformed anti-human leukocyte antigen antibodies and/or positive retrospective crossmatch. J Heart Lung Transplant. 2007;26:1163-1169.
259. Xydas S, Yang JK, Burke EM, Chen JM, Addonizio LJ, Mital SR, Itescu S, Hsu DT, Lamour JM. Utility of post-transplant anti-HLA antibody measurements in pediatric cardiac transplant recipients. J Heart Lung Transplant. 2005;24:1289-1296.
260. Kirk R, Edwards LB, Aurora P, Taylor DO, Christie JD, Dobbels F, Kucheryavaya AY, Rahmel AO, Stehlik J, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: Twelfth Official Pediatric Heart Transplantation Report-2009. J Heart Lung Transplant. 2009;28:993-1006.
261. Pahl E, Naftel DC, Kuhn MA, Shaddy RE, Morrow WR, Canter CE, Kirklin J; Pediatric Heart Transplant Study. The impact and outcome of transplant coronary artery disease in a pediatric population: a 9-year multi-institutional study. J Heart Lung Transplant. 2005;24:645-651.
262. Chang AT, Platt JL. The role of antibodies in transplantation. Transplant Rev (Orlando). 2009;23:191-198.
263. Ho EK, Vasilescu ER, Vlad G, Marboe CC, Addonizio LJ, Suciu-Foca N. HLA antibodies in pediatric heart transplantation. Pediatr Transplant. 2011;15:458-464.
264. Ho EK, Vlad G, Vasilescu ER, de la Torre L, Colovai AI, Burke E, Deng M, Schwartz J, Marboe C, Mancini D, Opelz G, Suciu-Foca N. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. Hum Immunol. 2011;72:5-10.
265. Rossano JW, Morales DL, Zafar F, Denfield SW, Kim JJ, Jefferies JL, Dreyer WJ. Impact of antibodies against human leukocyte antigens on long-term outcome in pediatric heart transplant patients: an analysis of the United Network for Organ Sharing database. J Thorac Cardiovasc Surg. 2010;140:694-699.e2.
266. Jacobs JP, Quintessenza JA, Boucek RJ, Morell VO, Botero LM, Badhwar V, van Gelder HM, Asante-Korang A, McCormack J, Daicoff GR. Pediatric cardiac transplantation in children with high panel reactive antibody. Ann Thorac Surg. 2004;78:1703-1709.
267. Kirk R, Edwards LB, Kucheryavaya AY, Aurora P, Christie JD, Dobbels F, Rahmel AO, Stehlik J, Hertz MI. The Registry of the International Society for Heart and Lung Transplantation: Thirteenth Official Pediatric Heart Transplantation Report-2010. J Heart Lung Transplant. 2010;29:1119-1128.
268. Lamour JM, Kanter KR, Naftel DC, Chrisant MR, Morrow WR, Clemson BS, Kirklin JK; Cardiac Transplant Registry Database; Pediatric Heart Transplant Study. The effect of age, diagnosis, and previous surgery in children and adults undergoing heart transplantation for congenital heart disease. J Am Coll Cardiol. 2009;54:160-165.
269. Shaddy RE, Hunter DD, Osborn KA, Lambert LM, Minich LLA, Hawkins JA, McGough EC, Fuller TC. Prospective analysis of HLA immunogenicity of cryopreserved valved allografts used in pediatric heart surgery. Circulation. 1996;94:1063-1067.
270. Hawkins JA, Breinholt JP, Lambert LM, Fuller TC, Profaizer T, McGough EC, Shaddy RE. Class I and class II anti-HLA antibodies after implantation of cryopreserved allograft material in pediatric patients. J Thorac Cardiovasc Surg. 2000;119:324-330.
271. Brancaccio G, Amodeo A, Ricci Z, Morelli S, Gagliardi MG, Iacobelli R, Michielon G, Picardo S, Parisi F, Pongiglione G, Di Donato RM. Mechanical assist device as a bridge to heart transplantation in children less than 10 kilograms. Ann Thorac Surg. 2010;90:58-62.
272. Amodeo A, Brancaccio G, Michielon G, Filippelli S, Ricci Z, Morelli S, Gagliardi MG, Iacobelli R, Pongiglione G, Di Donato RM. Pneumatic pulsatile ventricular assist device as a bridge to heart transplantation in pediatric patients. Artif Organs. 2010;34:1017-1022.
273. Gandhi SK, Huddleston CB, Balzer DT, Epstein DJ, Boschert TA, Canter CE. Biventricular assist devices as a bridge to heart transplantation in small children. Circulation. 2008;118:S89-S93.
274. Yang J, Schall C, Smith D, Kreuser L, Zamberlan M, King K, Gajarski R. HLA sensitization in pediatric pre-transplant cardiac patients supported by mechanical assist devices: the utility of Luminex. J Heart Lung Transplant. 2009;28:123-129.
275. O'Connor MJ, Menteer J, Chrisant MR, Monos D, Lind C, Levine S, Gaynor JW, Hanna BD, Paridon SM, Ravishankar C, Kaufman BD. Ventricular assist device-associated anti-human leukocyte antigen antibody sensitization in pediatric patients bridged to heart transplantation. J Heart Lung Transplant. 2010;29:109-116.
276. Chin C, Naftel D, Pahl E, Shankel T, Clark ML, Gamberg P, Kirklin J, Webber S. Cardiac re-transplantation in pediatrics: a multi-institutional study. J Heart Lung Transplant. 2006;25:1420-1424.
277. Feingold B, Bowman P, Zeevi A, Girnita AL, Quivers ES, Miller SA, Webber SA. Survival in allosensitized children after listing for cardiac transplantation. J Heart Lung Transplant. 2007;26:565-571.
278. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson IW, Glotz D, Iskandar SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, Valente M. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8:753-760.
279. Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1990;19:126-146.
280. Dowling RD, Jones JW, Carroll MS, Gray LA Jr. Use of intravenous immunoglobulin in sensitized LVAD recipients. Transplant Proc. 1998;30:1110-1111.
281. Pahl E, Crawford SE, Cohn RA, Rodgers S, Wax D, Backer CL, Mavroudis C, Gidding SS. Reversal of severe late left ventricular failure after pediatric heart transplantation and possible role of plasmapheresis. Am J Cardiol. 2000;85:735-739.
282. De Vlaminck I, Valantine HA, Snyder TM, Strehl C, Cohen G, Luikart H, Neff NF, Okamoto J, Bernstein D, Weisshaar D, Quake SR, Khush KK. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med. 2014;6:241-277.